On the public citation graph
Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study
0 signed · 163 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/jcph.714openalex-snapshot
Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib
inferredcites →https://doi.org/10.1016/j.jhep.2011.11.020openalex-snapshot
Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: A subgroup analysis
inferredcites →https://doi.org/10.1016/j.jhep.2012.02.016openalex-snapshot
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma
inferredcites →https://doi.org/10.1016/s1470-2045(16)30107-3openalex-snapshot
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
inferredcites →https://doi.org/10.1038/nature10144openalex-snapshot
Molecular mechanisms and clinical applications of angiogenesis
inferredcites →https://doi.org/10.1038/nrc3205openalex-snapshot
Targeting MET in cancer: rationale and progress
inferredcites →https://doi.org/10.1038/onc.2015.343openalex-snapshot
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
inferredcites →https://doi.org/10.1038/sj.bjc.6605017openalex-snapshot
Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis
inferredcites →https://doi.org/10.1056/nejmoa0708857openalex-snapshot
Sorafenib in Advanced Hepatocellular Carcinoma
inferredcites →https://doi.org/10.1093/annonc/mdw237.03openalex-snapshot
LBA-03 Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial
inferredcites →https://doi.org/10.1093/carcin/bgt372openalex-snapshot
Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma
inferredcites →https://doi.org/10.1093/jnci/92.3.205openalex-snapshot
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
inferredcites →https://doi.org/10.1111/cas.12891openalex-snapshot
Elevated hepatocyte growth factor expression as an autocrine c‐Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells
inferredcites →https://doi.org/10.1158/0008-5472.can-10-0489openalex-snapshot
HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
inferredcites →https://doi.org/10.1158/1078-0432.ccr-12-2791openalex-snapshot
Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma
inferredcites →https://doi.org/10.1158/1078-0432.ccr-13-2620openalex-snapshot
Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET
inferredcites →https://doi.org/10.1158/1535-7163.mct-11-0264openalex-snapshot
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
inferredcites →https://doi.org/10.1158/2159-8290.cd-11-0240openalex-snapshot
Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors
inferredcites →https://doi.org/10.1159/000462153openalex-snapshot
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib.
inferredcites →https://doi.org/10.1200/jco.2005.03.6723openalex-snapshot
Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma
inferredcites →https://doi.org/10.1200/jco.2008.18.8151openalex-snapshot
New Utility of an Old Marker: Serial α-Fetoprotein Measurement in Predicting Radiologic Response and Survival of Patients With Hepatocellular Carcinoma Undergoing Systemic Chemotherapy
inferredcites →https://doi.org/10.1200/jco.2010.32.4145openalex-snapshot
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
inferredcites →https://doi.org/10.1200/jco.2011.29.15_suppl.3010openalex-snapshot
Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors.
inferredcites →https://doi.org/10.1200/jco.2012.45.0494openalex-snapshot
Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial
inferredcites →https://doi.org/10.1200/jco.2012.48.4659openalex-snapshot
Cabozantinib in Progressive Medullary Thyroid Cancer
inferredcites →https://doi.org/10.1200/jco.2015.33.18_suppl.lba101openalex-snapshot
Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040.
inferredcites →https://doi.org/10.4251/wjgo.v8.i2.173openalex-snapshot
Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4195069openalex-extracted
Phase I/II Trial of Cabozantinib Plus Durvalumab in Advanced Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA): Phase Ib Safety and Efficacy Results
inferred← citeshttps://doi.org/10.1002/9781119756422.ch18openalex-snapshot
The Multidisciplinary Management of Primary Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1002/cncr.31257openalex-snapshot
Molecular signatures in hepatocellular carcinoma: A step toward rationally designed cancer therapy
inferred← citeshttps://doi.org/10.1002/hep.29913openalex-snapshot
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
inferred← citeshttps://doi.org/10.1002/jcph.1467openalex-snapshot
Updated Population Pharmacokinetic Model of Cabozantinib Integrating Various Cancer Types Including Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1002/med.21738openalex-snapshot
Targeting hepatocyte growth factor/c‐mesenchymal–epithelial transition factor axis in hepatocellular carcinoma: Rationale and therapeutic strategies
inferred← citeshttps://doi.org/10.1002/psp4.12602openalex-snapshot
Translational pharmacokinetic‐pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose
inferred← citeshttps://doi.org/10.1007/978-3-030-21540-8_11openalex-snapshot
Molecular-Targeted Therapies in Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1007/978-3-030-24432-3_59openalex-snapshot
Systemic Therapy of Advanced Liver Cancer
inferred← citeshttps://doi.org/10.1007/978-3-319-91977-5_7openalex-snapshot
Medical Therapy Options for Advanced Disease in Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1007/s00761-018-0463-3openalex-snapshot
Cabozantinib beim fortgeschrittenen hepatozellulären Karzinom
inferred← citeshttps://doi.org/10.1007/s10269-017-2712-2openalex-snapshot
Carcinome hépatocellulaire : nouveaux concepts, nouvelles molécules et nouvelles approches
inferred← citeshttps://doi.org/10.1007/s11523-019-00622-yopenalex-snapshot
Cabozantinib: A Review in Advanced Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1007/s11684-019-0728-2openalex-snapshot
Medical oncology management of advanced hepatocellular carcinoma 2019: a reality check
inferred← citeshttps://doi.org/10.1007/s11901-019-00489-7openalex-snapshot
The Current Landscape of Systemic Therapies for Advanced Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1007/s12029-018-0121-4openalex-snapshot
Hepatocellular Carcinoma: Review of Targeted and Immune Therapies
inferred← citeshttps://doi.org/10.1007/s12664-018-0915-0openalex-snapshot
Staging systems of hepatocellular carcinoma: A review
inferred← citeshttps://doi.org/10.1007/s40262-019-00740-wopenalex-snapshot
Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1007/s40265-020-01361-5openalex-snapshot
Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives
inferred← citeshttps://doi.org/10.1016/j.aohep.2023.101110openalex-snapshot
Liver decompensation is a frequent cause of treatment discontinuation and prognostic factor in intermediate-advanced HCC
inferred← citeshttps://doi.org/10.1016/j.arabjc.2021.103206openalex-snapshot
Concurrent detection of cabozantinib as an anticancer agent and its major metabolites in human serum using fluorescence-coupled micellar liquid chromatography
inferred← citeshttps://doi.org/10.1016/j.cdtm.2018.08.003openalex-snapshot
Systemic treatment for hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1016/j.cld.2020.07.008openalex-snapshot
Management of Side Effects of Systemic Therapies for Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1016/j.cllc.2018.12.018openalex-snapshot
Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non–Small-Cell Lung Cancer
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2020.103179openalex-snapshot
Milestones in the treatment of hepatocellular carcinoma: A systematic review.
inferred← citeshttps://doi.org/10.1016/j.ctrv.2018.05.006openalex-snapshot
Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond
inferred← citeshttps://doi.org/10.1016/j.ctrv.2021.102221openalex-snapshot
Cabozantinib: An evolving therapy for hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1016/j.dld.2020.12.001openalex-snapshot
Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.
inferred← citeshttps://doi.org/10.1016/j.dld.2023.10.028openalex-snapshot
Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association…
inferred← citeshttps://doi.org/10.1016/j.ejca.2017.09.011openalex-snapshot
Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours
inferred← citeshttps://doi.org/10.1016/j.jceh.2019.09.007openalex-snapshot
2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations
inferred← citeshttps://doi.org/10.1016/j.jhep.2018.03.019openalex-snapshot
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1016/j.jhepr.2024.101021openalex-snapshot
A phase Ib/II trial of capmatinib plus spartalizumab vs. spartalizumab alone in patients with pretreated hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1016/j.phrs.2023.106789openalex-snapshot
Upregulation of CSNK1A1 induced by ITGB5 confers to hepatocellular carcinoma resistance to sorafenib in vivo by disrupting the EPS15/EGFR complex
inferred← citeshttps://doi.org/10.1016/j.thromres.2024.05.002openalex-snapshot
Immunological role of Gas6/TAM signaling in hemostasis and thrombosis
inferred← citeshttps://doi.org/10.1016/j.ymthe.2024.08.001openalex-snapshot
Small-molecule-based targeted therapy in liver cancer
inferred← citeshttps://doi.org/10.1021/acsami.3c11909openalex-snapshot
pH-Responsive and Actively Targeted Metal–Organic Framework Structures for Multimodal Antitumor Therapy and Inhibition of Tumor Invasion and Metastasis
inferred← citeshttps://doi.org/10.1038/s41388-021-01863-wopenalex-snapshot
HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence
inferred← citeshttps://doi.org/10.1038/s41416-021-01559-8openalex-snapshot
Landscape of prognostic signatures and immunogenomics of the AXL/GAS6 axis in renal cell carcinoma
inferred← citeshttps://doi.org/10.1038/s41571-018-0073-4openalex-snapshot
Molecular therapies and precision medicine for hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1042/bsr20170827openalex-snapshot
A network meta-analysis of short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma
inferred← citeshttps://doi.org/10.1055/s-0037-1606254openalex-snapshot
Functional Imaging and Assessment of Antitumor Activity in Systemic Therapy for Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1056/nejmoa1717002openalex-snapshot
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1080/14656566.2017.1378346openalex-snapshot
An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1080/14656566.2018.1479398openalex-snapshot
Oral chemotherapy for the treatment of hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1080/14656566.2021.1892074openalex-snapshot
Advances in pharmacotherapeutics for hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1080/14737140.2017.1344553openalex-snapshot
Cabozantinib for the treatment of kidney cancer
inferred← citeshttps://doi.org/10.1080/14737140.2019.1585245openalex-snapshot
Systemic treatment of advanced hepatocellular cancer: new hope on the horizon
inferred← citeshttps://doi.org/10.1080/14737140.2019.1674141openalex-snapshot
Cabozantinib for the treatment of hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1080/14737159.2021.1987217openalex-snapshot
Predictive biomarkers for systemic therapy of hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1080/17474124.2021.1842732openalex-snapshot
Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocelluar carcinoma
inferred← citeshttps://doi.org/10.1093/annonc/mdx015openalex-snapshot
Cabozantinib: targeted therapy back to the future?
inferred← citeshttps://doi.org/10.1096/fj.202101507rropenalex-snapshot
A genome‐wide CRISPR activation screen reveals Hexokinase 1 as a critical factor in promoting resistance to multi‐kinase inhibitors in hepatocellular carcinoma cells
inferred← citeshttps://doi.org/10.1097/meg.0000000000003070openalex-snapshot
Comparative effectiveness and safety of second-line therapies and dosing regimens for advanced hepatocellular carcinoma: a network meta-analysis
inferred← citeshttps://doi.org/10.1097/ot9.0000000000000086openalex-snapshot
Comprehensive insights into systemic therapy for the whole-course management of hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1111/hepr.13191openalex-snapshot
Immune checkpoint blockade for the treatment of human hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1111/hepr.13445openalex-snapshot
Activation of extracellular signal‐regulated kinase is associated with hepatocellular carcinoma with aggressive phenotypes
inferred← citeshttps://doi.org/10.1111/pin.12895openalex-snapshot
Precision pathology analysis of the development and progression of hepatocellular carcinoma: Implication for precision diagnosis of hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1148/radiol.2021202289openalex-snapshot
Lack of Response to Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Abandon or Repeat?
inferred← citeshttps://doi.org/10.1155/2018/4763832openalex-snapshot
The Expanding Role of Systemic Therapy in the Management of Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.11569/wcjd.v27.i7.450openalex-snapshot
Progress in basic and clinical research of targeted drugs for primary hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1159/000488542openalex-snapshot
Cabozantinib as a Second-Line Agent in Advanced Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1159/000490378openalex-snapshot
Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience
inferred← citeshttps://doi.org/10.1159/000496439openalex-snapshot
Systemic Treatment for Advanced Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1159/000499765openalex-snapshot
Systemic Treatment Options in Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1177/17588359221107112openalex-snapshot
Cabozantinib for the treatment of solid tumors: a systematic review
inferred← citeshttps://doi.org/10.1186/s12876-022-02540-2openalex-snapshot
Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1186/s12943-019-1090-3openalex-snapshot
AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
inferred← citeshttps://doi.org/10.1186/s12964-024-01720-9openalex-snapshot
Role of liver sinusoidal endothelial cell in metabolic dysfunction-associated fatty liver disease
inferred← citeshttps://doi.org/10.1186/s12967-023-04521-9openalex-snapshot
Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
inferred← citeshttps://doi.org/10.1186/s13046-019-1412-8openalex-snapshot
Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma
inferred← citeshttps://doi.org/10.12998/wjcc.v9.i21.5754openalex-snapshot
Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis
inferred← citeshttps://doi.org/10.14309/ajg.0000000000000843openalex-snapshot
Integrating Genomics Into Clinical Practice in Hepatocellular Carcinoma: The Challenges Ahead
inferred← citeshttps://doi.org/10.14735/amko2020356openalex-snapshot
Systemic treatment for hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1634/theoncologist.2017-0335openalex-snapshot
Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma
inferred← citeshttps://doi.org/10.1634/theoncologist.2019-0563openalex-snapshot
Efficacy of Cabozantinib and Nivolumab in Treating Hepatocellular Carcinoma with RET Amplification, High Tumor Mutational Burden, and PD-L1 Expression
inferred← citeshttps://doi.org/10.17650/2686-9594-2022-12-4-41-51openalex-snapshot
Cabozantinib in hepatocellular cancer: from preclinical experiments to observational studies
inferred← citeshttps://doi.org/10.17998/jlc.18.1.17openalex-snapshot
Systemic Therapy for Advanced Hepatocellular Carcinoma: Targeted Therapy and Immunotherapy
inferred← citeshttps://doi.org/10.18632/oncotarget.18382openalex-snapshot
Precision medicine for hepatocellular carcinoma: driver mutations and targeted therapy
inferred← citeshttps://doi.org/10.20517/2394-5079.2018.21openalex-snapshot
Systemic therapies for hepatocellular carcinoma: a recap of the current status
inferred← citeshttps://doi.org/10.20517/2394-5079.2018.42openalex-snapshot
The fibroblast growth factor receptor pathway in hepatocellular carcinoma
inferred← citeshttps://doi.org/10.21037/cco-20-117openalex-snapshot
Systemic therapy for advanced hepatocellular carcinoma: targeted therapies
inferred← citeshttps://doi.org/10.21037/hbsn.2018.11.22openalex-snapshot
Cabozantinib for advanced hepatocellular carcinoma
inferred← citeshttps://doi.org/10.21037/jgo.2018.01.12openalex-snapshot
Second-line therapy in advanced upper gastrointestinal cancers: current status and new prospects
inferred← citeshttps://doi.org/10.21037/tcr-23-1333openalex-snapshot
Liver-directed moderately hypo-fractionated radiotherapy combined with pembrolizumab and bevacizumab for advanced hepatocellular carcinoma: a retrospective observational study of 23 cases
inferred← citeshttps://doi.org/10.2147/cmar.s202973openalex-snapshot
Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.2147/jhc.s157413openalex-snapshot
Potential of ramucirumab in treating hepatocellular carcinoma patients with elevated baseline alpha-fetoprotein
inferred← citeshttps://doi.org/10.2147/jhc.s169285openalex-snapshot
Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study)
inferred← citeshttps://doi.org/10.2147/jhc.s171396openalex-snapshot
Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI)
inferred← citeshttps://doi.org/10.2147/jhc.s195570openalex-snapshot
Profile of Cabozantinib for the Treatment of Hepatocellular Carcinoma: Patient Selection and Special Considerations
inferred← citeshttps://doi.org/10.2147/jhc.s268314openalex-snapshot
Second-Line Treatment Options for Hepatocellular Carcinoma: Current Landscape and Future Direction
inferred← citeshttps://doi.org/10.2147/jhc.s282209openalex-snapshot
Effect of Inhibiting Tumor Angiogenesis After Embolization in the Treatment of HCC with Apatinib-Loaded p(N-Isopropyl-Acrylamide-co-Butyl Methyl Acrylate) Temperature-Sensitive Nanogel
inferred← citeshttps://doi.org/10.2147/jhc.s300182openalex-snapshot
Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options
inferred← citeshttps://doi.org/10.2147/jhc.s383922openalex-snapshot
Expert Insights on Current Treatments for Hepatocellular Carcinoma: Clinical and Molecular Approaches and Bottlenecks to Progress
inferred← citeshttps://doi.org/10.2174/0115672018318595240902095514openalex-snapshot
Enhanced Therapeutic Potential of Liposome-Coated Bushen Jianpi Recipe for Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.2174/0929867327666201013162144openalex-snapshot
Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.2174/1386207326666221031121426openalex-snapshot
Acteoside (Verbascoside): A Prospective Therapeutic Alternative against Hepatocellular Carcinoma by Inhibiting the Expression of AXL, FGFR, BRAF, TIE2 and RAF1 Targets
inferred← citeshttps://doi.org/10.2174/1389200221999200918141239openalex-snapshot
Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis
inferred← citeshttps://doi.org/10.2174/1568026619666190620155613openalex-snapshot
Research Progress of Axl Inhibitors
inferred← citeshttps://doi.org/10.2217/fon-2017-0169openalex-snapshot
Cabozantinib in the treatment of hepatocellular carcinoma
inferred← citeshttps://doi.org/10.2217/fon-2017-0451openalex-snapshot
Novel Targeted Therapy Strategies for Biliary Tract Cancers and Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.2217/fon-2019-0026openalex-snapshot
Cabozantinib in Patients with Hepatocellular Carcinoma Failing Previous Treatment with Sorafenib
inferred← citeshttps://doi.org/10.2217/hep-2017-0020openalex-snapshot
Systemic treatments for hepatocellular carcinoma: challenges and future perspectives
inferred← citeshttps://doi.org/10.2217/hep-2019-0001openalex-snapshot
Current options and future possibilities for the systemic treatment of hepatocellular carcinoma
inferred← citeshttps://doi.org/10.31488/bjcr.160openalex-snapshot
Immune Checkpoint Inhibitors, New Therapies for HCC A Systematic Review of Clinical Registered Trials and Trials on-going
inferred← citeshttps://doi.org/10.3389/fcell.2020.00801openalex-snapshot
HGF/c-Met Axis: The Advanced Development in Digestive System Cancer
inferred← citeshttps://doi.org/10.3389/fonc.2021.752725openalex-snapshot
Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials
inferred← citeshttps://doi.org/10.3389/fonc.2022.958869openalex-snapshot
PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib
inferred← citeshttps://doi.org/10.3390/biomedicines8120547openalex-snapshot
Identification of Enzymes Oxidizing the Tyrosine Kinase Inhibitor Cabozantinib: Cabozantinib Is Predominantly Oxidized by CYP3A4 and Its Oxidation Is Stimulated by cyt b5 Activity
inferred← citeshttps://doi.org/10.3390/cancers11081086openalex-snapshot
New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.3390/cancers13112677openalex-snapshot
A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study
inferred← citeshttps://doi.org/10.3390/cancers13143426openalex-snapshot
Poor Response to Checkpoint Immunotherapy in Uveal Melanoma Highlights the Persistent Need for Innovative Regional Therapy Approaches to Manage Liver Metastases
inferred← citeshttps://doi.org/10.3390/cancers13153740openalex-snapshot
The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.3390/cancers14030621openalex-snapshot
Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances
inferred← citeshttps://doi.org/10.3390/ijms23073830openalex-snapshot
Solid Tumors and Kinase Inhibition: Management and Therapy Efficacy Evolution
inferred← citeshttps://doi.org/10.3390/ijms232214117openalex-snapshot
Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead—A Systematic Review
inferred← citeshttps://doi.org/10.3390/nano12162833openalex-snapshot
Hybrid Lipid Nanoformulations for Hepatoma Therapy: Sorafenib Loaded Nanoliposomes—A Preliminary Study
inferred← citeshttps://doi.org/10.3390/pharmaceutics14010041openalex-snapshot
Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment
inferred← citeshttps://doi.org/10.3410/f.733576189.793574887openalex-snapshot
Faculty Opinions recommendation of Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
inferred← citeshttps://doi.org/10.34172/apb.2024.061openalex-snapshot
Nanomedicine Strategies Utilizing Lipid-Based Nanoparticles for Liver Cancer Therapy: Exploring Signaling Pathways and Therapeutic Modalities
inferred← citeshttps://doi.org/10.3748/wjg.v25.i29.3870openalex-snapshot
Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma
inferred← citeshttps://doi.org/10.3748/wjg.v26.i16.1888openalex-snapshot
Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors
inferred← citeshttps://doi.org/10.3748/wjg.v29.i17.2571openalex-snapshot
Current and novel approaches in the pharmacological treatment of hepatocellular carcinoma
inferred← citeshttps://doi.org/10.3892/ol.2018.8656openalex-snapshot
The coordinated effects of Apatinib and Tripterine on the proliferation, invasiveness and apoptosis of human hepatoma Hep3B cells
inferred← citeshttps://doi.org/10.3892/ol.2019.10222openalex-snapshot
Significance of PD‑L1 clones and C‑MET expression in hepatocellular carcinoma
inferred← citeshttps://doi.org/10.3892/or.2021.8142openalex-snapshot
Association between the HGF/c‑MET signaling pathway and tumorigenesis, progression and prognosis of hepatocellular carcinoma (Review)
inferred← citeshttps://doi.org/10.4251/wjgo.v11.i10.788openalex-snapshot
Targeted agents for second-line treatment of advanced hepatocellular carcinoma
inferred← citeshttps://doi.org/10.4254/wjh.v14.i6.1074openalex-snapshot
Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options?
inferred← citeshttps://doi.org/10.5603/ocp.2019.0007openalex-snapshot
Cabozantinib in the treatment of advanced hepatocellular carcinoma patients
inferred← citeshttps://doi.org/10.5772/intechopen.1004995openalex-snapshot
Targeted Therapies for Hepatocellular Carcinoma Treatment
inferred← citeshttps://doi.org/10.6084/m9.figshare.26621467openalex-snapshot
Additional file 1 of Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
inferred← citeshttps://doi.org/10.6084/m9.figshare.26621470openalex-snapshot
Additional file 2 of Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
inferred← citeshttps://doi.org/10.6084/m9.figshare.26621473openalex-snapshot
Additional file 3 of Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
inferred← citeshttps://doi.org/10.70675/a6660468zb747z4a0czb963z900d06687ec7openalex-snapshot
Mécanismes d'immunosurveillance NKG2D et DNAM-1 dans le carcinome hépatocellulaire
inferred← citeshttps://doi.org/10.7150/jca.91175openalex-snapshot
Postoperative subphenotypes modified the hepatoma arterial-embolization prognostic score: A novel smHAP-II nomogram
inferred← citeshttps://doi.org/10.7573/dic.212577openalex-snapshot
Second-line treatment options in hepatocellular carcinoma
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.